Publicaciones en colaboración con investigadores/as de University of Colorado Cancer Center (17)

2022

  1. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer

    Cancer, Vol. 128, Núm. 9, pp. 1801-1811

2021

  1. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

    Blood, Vol. 138, Núm. 18, pp. 1768-1773

2020

  1. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

    Blood, Vol. 136, Núm. 10, pp. 1134-1143

2019

  1. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183

2017

  1. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer

    Lung Cancer, Vol. 104, pp. 45-51

2016

  1. Clinicopathologic features of advanced squamous NSCLC

    Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422

  2. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)

    Targeted Oncology

  3. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

    Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2066-2081

2015

  1. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

    Targeted Oncology, Vol. 10, Núm. 4, pp. 583-596

  2. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 763-774

2012

  1. EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials

    European Journal of Cancer, Supplement, Vol. 10, Núm. 1, pp. 66-75

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

  2. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 179-184

2010

  1. Integration of panitumumab into the treatment of colorectal cancer

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 1, pp. 16-26

2009

  1. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

    Molecular Cancer Therapeutics, Vol. 8, Núm. 6, pp. 1484-1493

2008

  1. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers

    Journal of Clinical Investigation, Vol. 118, Núm. 2, pp. 640-650